ArticleJournal of virology2012
Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge.
Article in Journal of virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 64 citations in OpenAlex.
- Generalized Eosinophilia Following Moderna COVID-19 Vaccine Administration: A Case Report.Academic forensic pathology · 2023Article
- Advances in nanotechnology application in biosafety materials: A crucial response to COVID-19 pandemic.Biosafety and health · 2022Review
- COVID-19: inflammatory responses, structure-based drug design and potential therapeutics.Molecular diversity · 2022Review
- Antiviral Immunity in SARS-CoV-2 Infection: From Protective to Deleterious Responses.Microorganisms · 2021Review
- Immunomodulation and immunotherapeutics of COVID-19.Clinical immunology (Orlando, Fla.) · 2021Review
- Monocytes and Macrophages, Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis.The Journal of infectious diseases · 2021Article
- Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections.Viruses · 2021Review
- Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry.Journal of clinical medicine · 2021Article
- Understanding the Host Innate Immune Responses against SARS-CoV-2 Infection and COVID-19 Pathogenesis.Immune network · 2021Review
- Article
- The Anti-inflammatory Effect of the Tricyclic Antidepressant Clomipramine and Its High Penetration in the Brain Might Be Useful to Prevent the Psychiatric Consequences of SARS-CoV-2 Infection.Frontiers in pharmacology · 2021Article
- SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage.Frontiers in immunology · 2021Article
- Curcumin and Piperine in COVID-19: A Promising Duo to the Rescue?Advances in experimental medicine and biology · 2021Article
- Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19.Frontiers in immunology · 2021Review
- Cellular events of acute, resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates.Nature communications · 2020Article
- Autoinflammatory and autoimmune conditions at the crossroad of COVID-19.Journal of autoimmunity · 2020Review
- Diacerein: A potential multi-target therapeutic drug for COVID-19.Medical hypotheses · 2020Article
- Autoimmunity to ACE2 as a possible cause of tissue inflammation in Covid-19.Medical hypotheses · 2020Article
- COVID-19: where have the lymphocytes gone?Internal medicine journal · 2020Article
- Principles Learned from the International Race to Develop a Safe and Effective COVID-19 Vaccine.ACS central science · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Our knowledge regarding immune-protective and immunopathogenic events in severe acute respiratory syndrome coronavirus (SARS-CoV) infection is limited, and little is known about the dynamics of the immune response at the primary site of disease. Here, an African green monkey (AGM) model was used to elucidate immune mechanisms that facilitate viral clearance but may also contribute to persistent lung inflammation following SARS-CoV infection. During primary infection, SARS-CoV replicated in the AGM lung for up to 10 days. Interestingly, lung inflammation was more prevalent following viral clearance, as leukocyte numbers peaked at 14 days postinfection (dpi) and remained elevated at 28 dpi compared to those of mock-infected controls. Lung macrophages but not dendritic cells were rapidly activated, and both cell types had high activation marker expression at late infection time points. Lung proinflammatory cytokines were induced at 1 to 14 dpi, but most returned to baseline by 28 dpi except interleukin 12 (IL-12) and gamma interferon. In SARS-CoV homologous rechallenge studies, 11 of the 12 animals were free of replicating virus at day 5 after rechallenge. However, incidence and severity of lung inflammation was not reduced despite the limited viral replication upon rechallenge. Evaluating the role of antibodies in immune protection or potentiation revealed a progressive increase in anti-SARS-CoV antibodies in lung and serum that did not correlate temporally or spatially with enhanced viral replication. This study represents one of the first comprehensive analyses of lung immunity, including changes in leukocyte populations, lung-specific cytokines, and antibody responses following SARS-CoV rechallenge in AGMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.